ArticleCancer cell2024
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
Open access · hybridAbstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
23.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.Frontiers in immunology · 2025Pooled it
- Genes, fuel, and fate in lung cancer.Biochemical Society transactions · 2026Review
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management.Cancer innovation · 2026Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Review
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine.International journal of molecular sciences · 2026Review
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer.Oncogene · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Article
- Alveolar organoids: from model systems to applications in respiratory diseases.Journal of translational medicine · 2026Review
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition.Cell death and differentiation · 2026Article
- Article
- HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.The Journal of clinical investigation · 2026Article
- Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.Cancer research communications · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- TRIM21-mediated ubiquitination of PARP1 regulated by the PI3K/AKT-STAT5A axis suppresses small cell lung cancer.Nature communications · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
40 authors at 14 institutions in 2 countries.
Xinyuan TongState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Ayushi S PatelLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Eejung KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Hongjun LiMOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Department of Automation, Tsinghua University, Beijing 100084, China.
Yueqing ChenState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Shuai LiLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Shengwu LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Julien DillyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Biological and biomedical sciences program, Harvard Medical School, Boston, MA 02115, USA.
Kevin S KapnerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ningxia ZhangDepartment of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
Yun XueState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Laura HoverMonoceros Biosystems, LLC, San Diego, CA 92129, USA.
Suman MukhopadhyayLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Fiona ShermanLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Khrystyna MyndzarLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Priyanka SahuLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Yijun GaoState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Fei LiDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Fuming LiShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200438, China.
Zhaoyuan FangZhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining 314400, China; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
Yujuan JinState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Juntao GaoInstitute for TCM-X, MOE Key Laboratory of Bioinformatics, Bioinformatics Division and Center for Synthetic and Systems Biology, BNRist, Tsinghua University, Beijing 100084, China.
Minglei ShiInstitute of Medical Innovation, Peking University Third Hospital, Beijing 100191, China.
Satrajit SinhaDepartment of Biochemistry, State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA.
Luonan ChenState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 200120, China; Key Laboratory of Systems Biology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou 310024, China; West China Biomedical Big Data Center, Med-X Center for Informatics, West China Hospital, Sichuan University, Chengdu 610041, China.
Yang ChenState Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing 100005, China.
Thian KheohMirati Therapeutics, San Diego, CA 92121, USA.
Wenjing YangMirati Therapeutics, San Diego, CA 92121, USA.
Itai YanaiLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA; Institute of Systems Genetics, New York University Langone Health, New York, NY 10016, USA.
Andre L MoreiraLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Vamsidhar VelchetiLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Benjamin G NeelLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.
Liang HuState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
James G ChristensenMirati Therapeutics, San Diego, CA 92121, USA.
Peter OlsonMirati Therapeutics, San Diego, CA 92121, USA.
Dong GaoState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Michael Q ZhangDepartment of Biological Sciences, Center for Systems Biology, The University of Texas, Richardson, TX 75080, USA. Electronic address: michael.zhang@utdallas.edu.
Andrew J AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: andrew_aguirre@dfci.harvard.edu.
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA. Electronic address: kwok-kin.wong@nyulangone.org.
Hongbin JiState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; School of Life Science and Technology, Shanghai Tech University, Shanghai 200120, China. Electronic address: hbji@sibcb.ac.cn.
NYU Langone Health · USChinese Academy of Sciences · CNBroad Institute · USMirati Therapeutics (United States) · USSun Yat-sen University · CNShanghai Medical College of Fudan University · CNCenter for Excellence in Molecular Cell Science · CNDana-Farber Cancer Institute · USPeking University · CNSecond Affiliated Hospital of Zhejiang University · CNThe University of Texas at Dallas · USTsinghua University · CNUniversity at Buffalo, State University of New York · USZhejiang University · CN
Funding
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancerR01CA276268 · NCI · DANA-FARBER CANCER INST · PI Andrew James Aguirre · 2023 to 2026
$2.2MNCI NIH HHS R01 CA276268
Abstract
KRAS
Indexed as
AcetonitrilesCarcinoma, Squamous CellLung NeoplasmsPiperazinesPyrimidinesAnimalsGenes, rasHumansMiceMutationProto-Oncogene Proteins p21(ras)AcetonitrilesadagrasibKRAS protein, humanPiperazinesProto-Oncogene Proteins p21(ras)Pyrimidinesadeno-to-squamous transition, ASTKRAS inhibitorKRT6ALKB1organoid
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.